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Objective. Lyme arthritis (LA) is characterized by
infiltration of inflammatory cells, mainly neutrophils
(polymorphonuclear cells [PMNs]) and T cells, into the
joints. This study was undertaken to evaluate the role of
the neutrophil-activating protein A (NapA) of Borrelia
burgdorferi in eliciting inflammation and in driving the
adaptive immune response.
Methods. Levels of NapA, interferon- (IFN),
interleukin-17 (IL-17), and T cell–attracting chemo-
kines were assessed by enzyme-linked immunosorbent
assay in synovial fluid from patients with LA. The
profile of T cells recruited into the synovia of patients
with LA was defined by fluorescence-activated cell sort-
ing analysis. NapA was intraarticularly injected into rat
knees, and the cells recruited in synovia were charac-
terized. The role of NapA in recruiting immune cells was
confirmed by chemotaxis assays using a Transwell sys-
tem.
Results. NapA, IFN, IL-17, CCL2, CCL20, and
CXCL10 accumulated in synovial fluid from patients
with LA. Accordingly, T cells obtained from these pa-
tients produced IFN or IL-17, but notably, some
produced both cytokines. NapA promoted neutrophil
and T lymphocyte recruitment both in vitro and in vivo.
Interestingly, the infiltration of T cells not only resulted
from the chemotactic activity of NapA but also relied on
the chemokines produced by PMNs exposed to NapA.
Conclusion. We provide evidence that NapA func-
tions as one of the main bacterial products involved in
the pathogenesis of LA. Accordingly, we show that, at
very early stages of LA, NapA accumulates and, in turn,
orchestrates the recruitment of inflammatory cells into
the joint cavity. Thereafter, with the contribution of
recruited cells, NapA promotes the infiltration of T cells
producing IL-17 and/or IFN.
Borrelia burgdorferi is a spirochetal bacterium
responsible for human Lyme disease, a multisystem
illness transmitted by ticks (1). Lyme disease usually
begins with the appearance of erythema migrans, a
characteristic expanding skin lesion (2). Within days or
weeks after the onset of local infection, bacteria may
spread through the bloodstream to different sites, caus-
ing meningitis, cranial or peripheral neuritis, carditis, or
musculoskeletal pain. After several months, severe and
chronic symptoms that mainly affect joints may develop
in untreated or inadequately treated patients (3); this
condition, defined as Lyme arthritis (LA), is character-
ized by joint swelling, synovial hypertrophy, vascular
proliferation, and infiltration of inflammatory cells (4).
The presence of B burgdorferi in connective tissue of the
joints of infected individuals likely plays an important
role in establishing the course of LA (5).
The recruitment of neutrophils (polymorphonu-
Supported by the Associazione Italiana per la Ricerca sul
Cancro and the Italian Ministry of University and Research, PRIN
Projects (grants to Drs. D’Elios and de Bernard), and by the Fonda-
zione Cariplo (grant 2011-0485 to Dr. de Bernard). Dr. Micheletti is
recipient of an Associazione Italiana per la Ricerca sul Cancro
fellowship.
1Gaia Codolo, PhD, Marina de Bernard, PhD: Venetian
Institute of Molecular Medicine and University of Padua, Padua, Italy;
2Fleur Bossi, PhD, Paolo Durigutto, PhD, Fabio Fischetti, MD,
Francesco Tedesco, MD: University of Trieste, Trieste, Italy; 3Chiara
Della Bella, PhD, Amedeo Amedei, BSc, Sofia D’Elios, BSc, Mario M.
D’Elios, MD: University of Florence, Florence, Italy; 4Marco Cim-
mino, MD: University of Genoa, Genoa, Italy; 5Alessandra Micheletti,
PhD, Marco A. Cassatella, MD: University of Verona, Verona, Italy.
Address correspondence to Marina de Bernard, PhD, Vene-
tian Institute of Molecular Medicine, Via Orus 2, 35129 Padua, Italy
(e-mail: marina.debernard@unipd.it); or to Mario M. D’Elios, MD,
Department of Internal Medicine, University of Florence, Viale
Morgagni 85, 50134 Florence, Italy (e-mail: delios@unifi.it).
Submitted for publication May 25, 2012; accepted in revised
form January 15, 2013.
1232
clear cells [PMNs]) to the site of infection is a critical
first step in the immune response to pathogens. In
experimental LA, but also in patients with LA, PMNs
are the primary cell type present during the acute
inflammatory phase, and they appear to be critical for
development of the disease (6,7). Accordingly, not only
are PMNs likely to be responsible for the tissue damage
that may occur upon extracellular release of granule
content but, more importantly, they may also play an
active role in driving an immune response that, instead
of being beneficial, contributes to the induction of LA
(7). However, the mechanism by which PMNs contribute
to LA has not yet been clarified.
The inflammation characterizing LA has tradi-
tionally been defined as a Th1 cell–mediated response;
however, recent studies have shown that LA is induced
by cytokines other than interferon- (IFN), because
experimental LA can occur and propagate even in
IFN-deficient mice (8,9). The disease paradigm based
solely on a Th1 cell–mediated inflammatory response
has been extended to include Th17 cells, a new subset of
helper T cells (7); indeed, inhibition of interleukin-17
(IL-17) prevents the development of arthritis in vacci-
nated mice challenged with B burgdorferi (10). Further-
more, T cells from the synovial fluid of patients with LA
produce IL-17 in response to neutrophil-activating pro-
tein A (NapA), a major antigen produced by B burgdor-
feri (11). Consistent with the fact that 2 major types of
T cells are involved in the pathogenesis of LA, there is a
predominance of some chemokines crucial for their
recruitment into the synovial fluid of patients, such as
CXCL10, which is specific for Th1 cells, and CCL2,
which is specific for both Th1 and Th17 cells (12).
Moreover, although it has not yet been evaluated in LA,
CCL20-mediated recruitment of Th17 cells into the
inflamed joints of patients with rheumatoid arthritis
(RA) has also been described (13).
The contribution of macrophages to the creation
of a milieu rich in chemoattractants for T cells in the
joint fluid of patients with LA has been established
(11,12,14). However, the possibility exists that PMNs are
also involved; these versatile cells, either spontaneously
or following appropriate stimulation, have been shown
to express and/or produce numerous cytokines and
chemokines (15).
We previously demonstrated that the immune
modulatory properties of the antigen NapA are relevant
for the differentiation of T cells toward the Th17
phenotype (11). However, we did not elucidate whether
NapA accumulates in the joint fluid of patients with LA.
Therefore, the potential participation of NapA in or-
chestrating the entire process of joint inflammation also
remained unexplored.
In this study, we demonstrate that the protein
NapA, which accumulates in the joint cavity of patients
with LA, recruits PMNs in the early stage of disease and
subsequently recruits T lymphocytes. We show that
NapA recruits T cells via the contribution of chemokines
released by PMNs. Recruited T cells include both Th1
and Th17 cells, as well as a subset producing both IFN
and IL-17. Taken together, our results show that NapA
is a major bacterial factor driving the generation of a
proinflammatory T cell response responsible for clinical
onset and histopathologic changes in LA.
PATIENTS AND METHODS
Patients. Synovial fluid was obtained from patients
with LA, patients with RA, and healthy individuals, with
informed consent and approval of the local ethics committee.
Synovial fluid was aspirated at the time of knee joint biopsy
that was performed for diagnostic or therapeutic reasons. Five
anti-NapA–seropositive European patients with LA (3 men
and 2 women with a median age of 51 years [7 years]),
defined according to the Centers for Disease Control and
Prevention case definition for the condition (16,17), were
included in the study. Three patients had an antibiotic-
refractory disease course, defined as persistent joint swelling
for 3 months after the start of at least a 4-week treatment
course with intravenous antibiotics, at least an 8-week regimen
of oral antibiotics, or both. The samples were obtained during
the period of active arthritis. Patients with antibiotic-refractory
arthritis had negative polymerase chain reaction (PCR) results
for B burgdorferi DNA in joint fluid or synovial tissue (11).
After antibiotic treatment, patients with antibiotic-
refractory arthritis were treated with nonsteroidal antiinflam-
matory drugs, intraarticular corticosteroids, or disease-
modifying antirheumatic drugs. Five women with mild RA
(mean  SD Disease Activity Score in 28 joints [18] using the
C-reactive protein level of 3.6  1.0), diagnosed according to
the American College of Rheumatology 1987 criteria (19),
were included in the study. The mean SD age of the patients
was 55.6  14.3 years, disease duration was 132.4  181.7
months, and all except 1 patient were positive for IgM rheu-
matoid factor and anti–cyclic citrullinated peptide. Five age-
matched healthy individuals were included as negative con-
trols.
Synovial fluid T cells from patients with LA. Synovial
fluid–derived T cells were purified as previously reported (11)
and stimulated with NapA in the presence of irradiated
autologous antigen-presenting cells; synovial fluid–derived
T cell lines were then expanded with IL-2. On day 15, T cell
blasts from each line were stimulated with 25 ng/ml phorbol
myristate acetate plus 1 g/ml ionomycin in the presence
of brefeldin A (1 g/ml). Cells were stained for surface
and intracellular markers, using the following monoclonal
antibodies for flow cytometry: PerCP-conjugated anti-CD4,
phycoerythrin-conjugated anti–IL-17, and fluorescein isothiocya-
nate (FITC)–conjugated anti-IFN (Becton Dickinson).
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Animals. Wistar rats were obtained from a colony kept
in the animal house at the University of Trieste, Italy. Male
rats weighing 230–260 gm were used in this study. The in vivo
experiments were performed in compliance with the guidelines
of European (86/609/EEC) and Italian (D.L.116/92) laws and
were approved by the Italian Ministry of University and
Research and by the University Institutional Committee. All
treatments were performed under total anesthesia induced
with 25 mg/kg bromoethanol (Sigma).
Cloning and protein purification. The cloning of
NapA, its expression, and its purification have been reported
previously (11). Briefly, the NapA gene was cloned and
expressed in Bacillus subtilis, and NapA was purified by
performing anion-exchange chromatography (Mono Q fast-
performance liquid chromatography; GE Healthcare), fol-
lowed by gel-filtration chromatography (Superdex 200 HR
10/30; GE Healthcare). Protein was concentrated using a
Vivaspin ultrafiltration system (Sartorius), and the final prod-
uct was checked for purity in a Coomassie brilliant blue–
stained gel and analyzed by Western blotting with a specific
polyclonal antibody (20).
Enzyme-linked immunosorbent assay (ELISA) for
NapA quantification in synovial fluid. A 96-well plate was
coated overnight with 50 l/well of synovial fluid from healthy
donors, patients with LA, and patients with RA (diluted 1:4 in
phosphate buffered saline [PBS]). Each well was incubated
with a rabbit anti-NapA polyclonal antibody (20) followed by
horseradish peroxidase (HRP)–conjugated anti-rabbit IgG.
Plates were developed with tetramethylbenzidine (TMB) and
read at 450 nm using a Packard Fusion microplate analyzer.
The amount of NapA in each sample was determined by
referring to a standard curve.
ELISA for revealing anti-NapA antibodies in synovial
fluid. Synovial fluid samples from 2 patients with LA and 1
patient with RA were added to a 96-well plate previously
coated with purified recombinant NapA (1 g/well). HRP-
conjugated anti-human IgG was added to each well before
development with TMB. Absorbance was read at 450 nm using
a Packard Fusion microplate analyzer. The acquired values
were referred to a standard curve obtained using known
concentrations of rabbit IgG anti-NapA.
In vivo NapA and outer surface protein A (OspA)
administration. NapA (50 l of sterile saline containing 6 g
or 20 g of the protein) or OspA (50 l of sterile saline
containing 1 ng of the protein) was administered to rats by
intraarticular injection into the right knee, while vehicle (saline
only) was injected into the left knee. The concentrations of
NapA- or OspA-containing solutions (420 g/ml or 20 ng/ml,
respectively) were 20-fold higher than those that exerted the
maximum stimulation of human monocytes in vitro, in terms
of cytokine production. In the case of NapA, a lower amount
of protein was also tested. At different times postinjection
(2 hours and 2 days), the rats were killed, and the periarticular
tissue of the knee joints was gently removed to expose the
intraarticular cavity. The intraarticular cavity was washed with
2 ml of saline, and the total cell content in the synovial lavage
was determined with a Coulter Counter ZB1 (Beckman
Coulter). The amount of PMNs was estimated by measuring
the myeloperoxidase content (21). After cytocentrifugation,
the percentage of lymphocytes/monocytes was determined by
hematoxylin and eosin staining.
Immunohistochemical analysis. Rat knee joints were
fixed for 6 days in 10% buffered formalin, decalcified for 5
days in Decalcifier I (Bio-Optica), and embedded in paraffin.
Sections (6–8 m) of paraffin-embedded specimens were used
for immunohistochemical analysis.
IFN- and IL-17–positive cells present in the joint
synovium were revealed on paraffin-embedded sections of the
knee articulation by rabbit anti-rat IFN IgG (Hycult) or by
rabbit anti-rat IL-17 IgG (Santa Cruz Biotechnology) for 60
minutes at room temperature. Sections were further exposed
to anti-rabbit IgG, using a Vectastain ABC kit (Vector)
according to the manufacturer’s instructions.
Cell purification and culture. PMNs were enriched
(99.7% purity) from Ficoll-Paque–isolated granulocytes (ob-
tained from the peripheral blood of healthy donors) by posi-
tively removing all contaminating cells using an EasySep
Human Neutrophil Enrichment Kit (StemCell Technologies)
(22). PMNs were suspended in RPMI 1640 medium supple-
mented with 10% low-endotoxin fetal bovine serum (FBS;
EuroClone), and stimulated with 20 g/ml NapA at various
time points. Cells were harvested for quantification of chemo-
kines in the culture supernatants.
For evaluation of CD4 T cell chemotaxis, PMNs
were cultured in RPMI 1640 with 10% FBS in the presence of
20 g/ml NapA or saline plus 100 ng/ml IFN. After 24 hours
of culture, supernatants were collected and kept at80°C until
used in chemotaxis assays.
Human CD4 T lymphocytes from healthy donors
were purified by negative selection using a RosetteSep Kit
(StemCell Technologies) according to the manufacturer’s in-
structions. Briefly, RosetteSep enrichment cocktail was added
to buffy coat (50 l/ml) and incubated for 20 minutes at room
temperature. The sample was diluted with an equal volume of
PBS supplemented with 2% fetal calf serum (FCS) and layered
on Ficoll-Paque density-gradient medium (GE Healthcare).
After centrifugation (1,200g) for 20 minutes at room temper-
ature without brakes, T lymphocytes were collected and
washed twice with PBS supplemented with 2% FCS. Cells were
then resuspended in RPMI 1640 medium supplemented with
10% FCS.
Endothelial cell culture. Human umbilical vein endo-
thelial cells (HUVECs) were isolated from 3–5 normal human
umbilical cords by collagenase digestion and grown in tissue
culture plates (Costar) coated with 2% endotoxin-free gelatin
(23). HUVECs from the first passage were used. Cells were
kept in culture in Medium 199 supplemented with 20%
newborn calf serum (Invitrogen), 50 g/ml heparin, 100
units/ml penicillin, 100 g/ml streptomycin (Sigma), and 50
g/ml endothelial growth supplement (Immunological Sci-
ences) (24).
Chemotaxis assay. Polymorphonuclear cells (2  106/
ml) were added to the upper chamber of a polycarbonate
(PET) insert of a 24-well Transwell apparatus (Costar), while
RPMI 1640 medium (with or without 20 g/ml NapA or 100
nM fMLP) was added to the lower chamber. After 1 hour of
incubation, PMNs that had migrated into the lower chamber
were collected and counted using a CyQuant cell proliferation
assay kit (Invitrogen). To evaluate the chemokinetic activity of
NapA, the protein was added at the same concentration (20
g/ml) in both the upper and lower chambers. After 1 hour of
incubation, PMNs that had migrated into the lower chamber
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were collected and counted. To verify the effect of anti-NapA
antibodies on the chemotactic activity of NapA, we performed
the chemotaxis assay by applying to the lower chamber 20
g/ml NapA alone or 20 g/ml NapA plus increasing concen-
trations of rabbit anti-NapA antibody (from 20 g/ml to 500
g/ml). For a positive control 100 nM fMLP was used. When
synovial fluid was used as a source of anti-NapA antibodies,
fluid samples diluted 1:4 in culture medium together with
NapA were applied to the lower chamber. After 1 hour of
incubation, PMNs that had migrated into the lower chamber
were collected and counted.
CD4 T lymphocytes (2  106/ml) were added to the
upper chamber of the Transwell apparatus, while NapA or
NapA-conditioned PMN culture medium was added to the
lower chamber. The same experiment was performed in the
presence of 1 M cycloheximide (CHX). When required,
NapA-conditioned PMN culture medium was preincubated
for 30 minutes with the blocking antibodies anti-CCL2, anti-
CXCL10 (5 g/ml; PeproTech), or anti-CCL20 (5 g/ml; R&D
Systems) or with their isotype-related antibodies (5 g/ml;
BioLegend), and added to the bottom chamber. After a 2-hour
incubation, migrated T lymphocytes were harvested from the
lower chamber, and specific enzyme-linked immunospot
(ELISpot) assay kits (eBioscience) were used to assess their
ability to produce IFN, IL-17, or IL-4. When the chemotaxis
assay was performed through an endothelial monolayer,
HUVECs (2  105) were seeded onto 2% gelatin-coated
polycarbonate (PET) inserts of a 24-well Transwell system and
were used 5 days after plating. The formation of an intact
monolayer on the insert was evaluated by adding FITC-labeled
bovine serum albumin (BSA) (1 mg/ml) to the upper chamber,
and after 5 minutes, the amount of labeled BSA passed into
the lower chamber was measured using a FLUOstar micro-
plate reader (SLT Labinstruments). Transwells were used only
when the intensity of fluorescence in the lower chamber was
negligible. The pore sizes of filters used for the chemotaxis
assay were 3 m for PMNs and 5 m for T cells.
Chemokine and cytokine measurements. Chemokine
content was quantified both in culture supernatants from the
PMNs (10  106/ml) exposed to 20 g/ml NapA (in the
presence or absence of 100 ng/ml IFN) and in synovial fluid
from patients with LA. Quantification of CCL2 and CXCL10
was performed using a specific multichemokine detection kit
(Milliplex MAP; Millipore). The IFN and IL-17 content in
synovial fluid from patients with LA and in synovial fluid from
healthy subjects was measured using a specific multicytokine
detection kit (Milliplex MAP). Data were analyzed using
Bio-Plex Manager software (Bio-Rad). Quantification of
CCL20 was performed using a specific ELISA (R&D Systems).
For the multicytokine detection kit, the sensitivity threshold
was 3 pg/ml, while it was 12 pg/ml for the CCL20 ELISA kit.
Statistical analysis. Data are reported as the mean 
SD. Student’s t-test was used for statistical analysis of the
differences between experimental groups. P values less than or
equal to 0.05 were considered significant.
RESULTS
Accumulation of NapA within synovia of patients
with LA. The presence of B burgdorferi in connective
tissue of the joints is required for the development of
arthritis (5). However, the chemical nature of the bac-
terial factor(s) responsible for the disease remains un-
known. In order to verify whether NapA, a major
antigen produced by B burgdorferi, might be involved in
triggering and sustaining joint inflammation, we started
by testing for the presence of NapA in the synovial fluid
of patients with LA. Indeed, our recent finding that
NapA-specific Th17 lymphocytes accumulate within the
Figure 1. Quantification of neutrophil-activating protein A (NapA)
and anti-NapA in the synovial fluid of patients with Lyme arthritis
(LA). A, Presence of NapA in synovial fluid obtained from 5 patients
with LA (L), 5 patients with rheumatoid arthritis (RA), and 5 healthy
controls (C), as determined using a specific enzyme-linked immu-
nosorbent assay (ELISA). The NapA content in each sample was
determined by referring to a standard curve.   P  0.001. B,
Presence of anti-NapA antibodies as determined by ELISA in 2
patients with LA and 1 patient with RA. Bars show the mean  SD.
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synovial cavity of patients with LA (11) suggested the
possibility that the antigen was released by the bacte-
rium in that niche.
An ELISA performed using synovial fluid iso-
lated from 5 patients with LA revealed the presence of
NapA at a concentration that was similar among the
different samples (range 50–65 ng/ml). In contrast,
NapA was not detectable in synovial fluid from either
patients with RA or healthy control subjects (Figure
1A). The concentration of NapA detected in human
synovia was probably underestimated: it reflected not
only a certain degree of dilution, but most importantly, it
was influenced by the presence of proteases. Indeed, a
dominant feature of inflammatory tissue is the presence
of proteolytic activity, due partly to the fibrinolytic
system and partly to other proteases derived from
plasma, leukocytes, or other types of cells in the area of
inflammation (25). Notably, specific anti-NapA antibod-
ies were observed in synovial fluid from patients with LA
but were not detectable in synovial fluid from patients
with RA (Figure 1B).
NapA-induced recruitment of PMNs and T lym-
phocytes in rat synovia. We next examined whether the
administration of NapA into rat knees was able to
provoke inflammation. For this purpose, the effect of
intraarticular injection of 2 different amounts of NapA
in rats was evaluated and compared with that induced by
injection of OspA, another Borrelia immunodominant
antigen (26), as well as with that induced by saline alone.
Analysis of the cell content in lavage fluid from rat knees
Figure 2. Leukocyte recruitment triggered by neutrophil-activating protein A (NapA) in rat synovia. A, Differential count of cells accumulated in
the synovial cavity of rats treated with NapA, outer surface protein A (OspA), or saline (vehicle) for 2 hours (left) or 2 days (right). The numbers
of polymorphonuclear cells (PMNs) were estimated by measuring the myeloperoxidase content, and lymphocytes/monocytes (LMs) were counted
following hematoxylin and eosin staining. Bars show the mean  SD.   P  0.01;   P  0.001. B, Immunohistochemical staining of rat
synovial membranes for interferon- (IFN) and interleukin-17 (IL-17), 2 days postinjection. Original magnification  200.
1236 CODOLO ET AL
injected with NapA revealed a distinct recruitment of
PMNs 2 hours postinjection (Figure 2A), which is con-
sistent with the fact that PMNs are the first cells
recruited to the site of infection (27). Notably, 2 days
after NapA administration, the majority of cells col-
lected in lavage fluid were lymphocytes/monocytes (Fig-
ure 2A). No significant difference was appreciable be-
tween the 2 doses of NapA administered; interestingly,
however, OspA was much less effective than NapA in
recruiting cells into synovia.
Immunohistochemical analysis of rat synovial tis-
sue revealed marked IFN and IL-17 staining in NapA-
treated rats (the signal was slightly less intense in rats
receiving the lower dose of NapA), while no staining was
observed in tissue obtained from OspA-treated rats or
saline-treated rats (Figure 2B). These observations are
consistent not only with various studies indicating that
IFN is a key modulator of arthritis development but
also with more-recent evidence supporting IL-17 as a
possible mediator of LA (11,12). These results demon-
strate that once NapA is present in the joint cavity, it
triggers the recruitment of both PMNs and lymphocytes
and induces the production of IFN and IL-17.
Effect of PMNs recruited by NapA on migration
of CD4 T cells that produce IFN and IL-17. To
evaluate whether NapA had chemotactic activity, we
monitored the passage of PMNs and lymphocytes across
a Transwell insert following application of NapA to the
lower chamber. Counting the number of cells that
migrated 1 hour after the application of the stimulus
revealed that NapA promoted movement of PMNs
toward the lower chamber, although at a lower level than
that induced by fMLP, a classic PMN activator (28,29)
(Figure 3A). Notably, no migration was appreciable
when NapA was added to both the upper and lower
chambers (data not shown), permitting the exclusion of
random movement of PMNs due to an eventual chemo-
kinetic effect of NapA.
Migration of PMNs promoted by NapA was not
impaired by anti-NapA antibodies, neither those accu-
mulated in the synovial cavity of patients with LA nor
those raised in rabbits following immunization with
recombinant NapA (data not shown). This observation
suggests that the anti-NapA humoral immune response
does not exert blocking action on the chemotactic activ-
ity of NapA.
The same experimental approach was used to
verify whether NapA was also able to recruit T lympho-
cytes, as suggested by the results obtained with in vivo
administration. We evaluated the chemotactic activity
of NapA, but because T lymphocyte recruitment in vivo
was subsequent to that of PMNs, we also examined the
effects of the supernatant collected from PMNs exposed
to NapA for 24 hours (referred to as NapA-conditioned
Figure 3. Chemotaxis of PMNs and CD4 T lymphocytes induced by
NapA. A and B, Quantification of the migration of PMNs and
lymphocytes across a Transwell insert following application of NapA to
the lower chamber, in the absence (A) or presence (B) of human
umbilical vein endothelial cell–derived endothelium grown onto a
Transwell filter. PMNs (2  106/ml) were added to the upper chamber
of a Transwell system, and medium (with or without 20 g/ml NapA
or 100 nM fMLP) was added to the lower chamber. After 1 hour of
incubation, the PMNs that had migrated into the lower chamber were
collected and counted. C and D, Quantification of spot-forming cells
(SFCs) in the absence (C) or presence (D) of endothelium. CD4 T
lymphocytes (2  106/ml) were added to the upper chamber of a
Transwell system, and NapA, supernatants from NapA-stimulated
PMNs, or supernatants from PMNs exposed to vehicle were added to
the lower chamber. After 2 hours, CD4 T lymphocytes were collected
from the lower chamber, and their profiles were determined in
enzyme-linked immunospot microplates coated with anti-IFN, anti–
IL-17, or anti–IL-4 antibodies. Bars show the mean  SD.   P 
0.01;   P  0.001. See Figure 2 for other definitions.
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medium of PMNs). The 24-hour stimulation of PMNs
with NapA was carried out in the presence of IFN, to
optimize the induction of chemokines for T cells (30–
33). Notably, IFN accumulates in the synovial fluid of
patients with LA (see below). Therefore, total CD4 T
cells were added to the upper chamber, and 2 hours after
the administration of the stimuli, cells that had migrated
were collected and analyzed for their profile. We ob-
served that NapA was chemoattractant for T cells,
directly and indirectly, by means of PMNs. Recruited T
cells produced IFN or IL-17 but not IL-4 (Figure 3C);
this observation suggested that both mechanisms trig-
gered the recruitment of specific T cell subsets.
Notably, a similar migration of PMNs and lym-
phocytes also occurred in the presence of an endothelial
monolayer grown onto the Transwell filter, suggesting
that even if endothelium activation occurred in the
presence of stimuli, it did not contribute to NapA-
mediated cell recruitment (Figures 3B and D).
Finally, in order to exclude the possibility that the
migration of CD4 T lymphocytes was attributable to
their endogenous production of chemoattractant factors,
we evaluated T cell migration in the presence of CHX,
to block protein synthesis in T cells. We did not observe
any difference in T cell migration ability in response to
NapA or NapA-conditioned supernatants from PMNs,
regardless of the presence of CHX (data not shown).
Role of NapA in stimulating PMNs to release
chemokines recruiting Th1 and Th17 cells. PMNs are
known to produce biologically functional levels of CCL2,
CCL20, and CXCL10 in response to lipopolysaccharide
(LPS) plus IFN (30–32). It was previously demon-
strated that PMN-derived CCL20 induces a migratory
response of CCR6-expressing dendritic cells (30,33) and
T lymphocytes (34), whereas PMN-derived CXCL10
induces migration of CXCR3-expressing lymphocytes
(32). Importantly, CCR6 and CXCR3 receptors are
typically expressed by Th17 and Th1 cells, respectively
(14,35). Moreover, it was demonstrated that CCL2
cooperates with either CCL20 or CXCL10 in inducing
Th17 or Th1 lymphocyte recruitment, supporting the
notion that there is crosstalk between PMNs and T cells
(34).
Therefore, based on the observation that NapA-
conditioned supernatants from PMNs recruited CD4
T cells producing IFN and/or IL-17 (Figure 3), we
evaluated the possibility that NapA could activate PMNs
(99.7% purity) to produce CCL2, CCL20, and
CXCL10. As shown in Figure 4, we observed that NapA
promotes the release of all 3 chemokines to a compara-
ble extent (range 15–25 pg/ml). When IFN was present,
the NapA-induced release of CCL2 and CXCL10 was
significantly enhanced, and the effect was synergistic
(Figure 4). Interestingly, the addition of IFN reduced
the secretion of CCL20, in contrast to what was observed
with the other Toll-like receptor agonist, LPS (30). This
unusual result, which suggests interplay between the
signaling cascades triggered by NapA and IFN, de-
serves further investigation.
Figure 4. Chemokine production by polymorphonuclear cells (PMNs) stimulated with neutrophil-activating protein A (NapA). The production of
CCL2, CCL20, and CXCL10 in the culture supernatant from NapA- or saline-treated PMNs (in the presence or absence of interferon- [IFN])
was determined by enzyme-linked immunosorbent assay after 20 hours of stimulation. Bars show the mean SD results of 3 experiments conducted
with different cell preparations.   P  0.05;   P  0.001.
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T cells recruited by NapA belong to the Th1,
Th17, and Th1/Th17 cell subsets. In order to clarify
whether CCL2, CCL20, and CXCL10 produced by
PMNs treated with NapA plus IFN were involved in
the recruitment of IFN- and IL-17–producing T cells,
we preincubated NapA-conditioned supernatants of
PMNs with specific blocking (or isotype-related) anti-
bodies. These supernatants were then applied to the
lower chambers of the Transwell system after total
CD4 T lymphocytes were added to the upper cham-
bers. Migrated cells were analyzed for the production of
IFN and IL-17 by ELISpot assay, as described in
Patients and Methods. Neutralization of CCL2, CCL20,
or CXCL10 reduced, at variable but significant levels,
the recruitment of both IFN- and IL-17–producing
CD4 T cells. Notably, simultaneous blockade of all 3
chemokines resulted in the most extensive reduction in
T cell chemotaxis (Figure 5). Isotype control antibodies
were ineffective.
Collectively, these results provide support for a
cooperative action by PMN-derived CCL2, CCL20, and
CXCL10 in the recruitment of IFN- and IL-17–
producing CD4 T lymphocytes. Moreover, they sug-
gest that T lymphocytes that are able to produce both
IFN and IL-17 are involved in a NapA-mediated
immune response related to the pathogenesis of LA. To
verify such an hypothesis, T cell lines specific for NapA,
obtained from mononuclear cells isolated from the
synovial cavity of 5 patients with LA (11), were assayed
for their IFN and IL-17 content by cytofluorometry
(Figure 6A). Our analysis revealed that the major pro-
portion of T cells were IL-17 producers (9%  2.3%),
although IFN producers were also retrieved (6.4% 
1.7%). Interestingly, however, a relevant proportion of
T cells produced both cytokines (7.08%  1.38%).
Consistently, we were able to quantify the documented
accumulation of IFN in synovial fluid from patients
with LA (12), but notably, we also observed the accu-
mulation of IL-17 (Figure 6B).
Finally, in order to corroborate the in vivo data,
we analyzed the chemokine content of synovial fluid
obtained from the patients with LA. In accordance with
a previous report (12), we detected CCL2 and CXCL10.
Additionally, we demonstrated for the first time that
CCL20 also accumulates in the synovial cavity of pa-
tients with LA (Figure 6C).
DISCUSSION
Arthritis is a well-documented complication that
follows infection with the tick-borne spirochete B burg-
Figure 5. Recruitment of IFN- and interleukin-17 (IL-17)–positive
CD4 T lymphocytes by PMNs stimulated with NapA together with
IFN or IL-17. CD4 T lymphocytes (2  106/ml) were added to the
upper chamber of a Transwell system, and supernatants from NapA/
IFN-stimulated PMNs preincubated with chemokine-blocking anti-
bodies (or with isotype-related antibodies) were added to the lower
chamber. After 2 hours, CD4 T lymphocytes were collected from the
lower chamber, and their profiles were determined using enzyme-
linked immunospot microplates coated with anti-IFN or anti–IL-17
antibodies. Bars show the mean  SD results of 4 experiments
conducted with different cell preparations.   P  0.01;   P 
0.001 versus isotype control antibodies, by Student’s t-test. See Figure
4 for other definitions.
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dorferi. The severity of arthritis can range from mild to
moderate inflammation of the joints that develops
months after infection, to a chronic, debilitating osteo-
arthropathy with destruction of cartilage and erosion of
bone that develops in a subset of patients within a few
years. After dissemination of the spirochete from the
skin to the joint, macrophages, T cells, B cells, and
plasma cells infiltrate the synovial tissue, while joint fluid
contains large numbers of PMNs.
The recruitment of PMNs into the infected joint
appears to be a prerequisite for the development of LA,
and these cells have been proposed to play a nonphago-
cytic immunoregulatory role (7,36). However, this issue
remains quite controversial, because some studies
showed that arthritis develops independently of the
presence of PMNs (36,37). Another missing piece of the
puzzle concerns the bacterial factor(s) that are respon-
sible for the recruitment of PMNs.
Once B burgdorferi is disseminated from the site
of inoculation, it establishes residence in the joint tissue;
however, whether the bacterium survives for a long time
in the synovial fluid is a matter of debate. Indeed,
although almost all patients with LA have positive PCR
results for detection of B burgdorferi DNA in synovial
fluid (5,38), only 2 cases have been reported in which the
bacterium itself was recovered from this site, and in
neither case was it possible to subculture the isolate
(39,40). Therefore, the idea that emerges is that in the
synovial fluid of patients with LA, these bacteria are
either moribund or dead (41), and the release of bacte-
rial antigens in this context is absolutely expected.
Interestingly, it has been recently proposed that retained
spirochetal antigens might perpetuate synovial inflam-
mation even after eradication of the spirochete from the
joint (through antibiotic therapy), giving rise to chronic
synovitis (6).
In a previous study, we demonstrated that pa-
tients with LA had a humoral immune response to the
neutrophil-activating protein NapA, while patients with
earlier manifestations of the disorder (erythema migrans
Figure 6. Involvement of T lymphocytes that produce both IFN and interleukin-17 (IL-17) in a NapA-mediated immune response related to the
pathogenesis of Lyme arthritis (LA) A, NapA-driven IFN and IL-17 production by synovial fluid CD4 T cells from patients with LA. Synovial
fluid T cells from 5 patients with LA (L1–L5) were stimulated with NapA in the presence of irradiated autologous antigen-presenting cells. B and
C, Accumulation of IFN and IL-17 (B) and chemokines involved in recruiting Th1 and Th17 cells (C) in the knee joint cavity of patients with LA.
Total amounts of IFN, IL-17, CCL2, CCL20, and CXCL10 were measured in synovial fluid from the same 5 patients with LA as in A and from
5 healthy control subjects (C1–C5). Bars show the mean  SD.   P  0.001. See Figure 4 for other definitions.
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and facial palsy) had minimal or no reactivity with this
antigen (11). Moreover, we showed that NapA is en-
dowed with immune modulatory properties that reflect
the activation of PMNs and monocytes, which are in-
duced to release cytokines that are crucial for the
induction of Th17 cell responses. It is noteworthy that
NapA-specific T cells were mainly confined to the
synovial fluid, because IL-17 production could not be
detected after stimulation of peripheral blood T cells
from the same patients with LA. These latter data,
suggesting that NapA could be one of the spirochetal
antigens that accumulate in the joint, have been con-
firmed in the present study. Indeed, we demonstrated
that NapA is retained in the synovial fluid of patients
with LA.
In addition, using a rat model of arthritis, we
observed that intraarticular injection of NapA triggered
the accumulation of inflammatory and immune cells:
PMNs accumulated as early as 2 hours after injection,
and lymphocytes/monocytes accumulated 2 days after
injection. In addition to monocyte/macrophages, the
latter population included IFN- and IL-17–producing
cells, as revealed by relevant staining of the 2 cytokines
on the synovial membrane of NapA-injected rats.
Notably, we also observed that NapA per se
exerted chemotactic activity for PMNs and T lympho-
cytes without involving chemokines of endothelial ori-
gin. Moreover, despite the high concentration of anti-
NapA antibodies in synovial fluid from patients with LA,
these antibodies did not impair the NapA-induced re-
cruitment of PMNs (data not shown).
The role of chemokines released by Borrelia-
stimulated macrophages in the homing of T cells to
infected joints is well established (14). We therefore
investigated whether NapA could stimulate recruited
PMNs to release chemoattractants that would partici-
pate in guiding the adaptive immune response in pa-
tients with LA. We observed that NapA-stimulated
PMNs released CCL2, CCL20, and CXCL10. Together
with CCL2, CCL20 is involved in the recruitment of
Th17 lymphocytes, while CXCL10, together with CCL2,
induces migration of CXCR3-expressing Th1 effector
cells (34). Therefore, it is expected that NapA, via the
involvement of PMNs, recruits both Th1 and Th17 cells;
this is consistent with the synovial staining we observed
in NapA-injected joints. Alternatively, the fact that these
chemokines were crucial in recruiting IFN- and IL-17–
producing cells was confirmed by evidence showing that
the application of anti-CCL2, anti-CCL20, and anti-
CXCL10 blocking antibodies significantly reduced T cell
recruitment promoted by NapA-conditioned superna-
tants of PMNs. In accordance with these data, we
observed the accumulation of not only IFN and IL-17
in synovial fluid of patients with LA, but also the
accumulation of the 3 chemokines that we demonstrated
to be produced by PMNs exposed to NapA. Finally, we
report that some T cells recruited by NapA-stimulated
PMNs belong to the subset that produces both IFN and
IL-17, and notably, such a subset was detectable in
patients with LA (42–44).
Collectively, our data highlight the role of the
NapA antigen in orchestrating the innate and adaptive
immune response during the development of LA. More-
over, our data support the notion that other than
monocyte/macrophages (14), PMNs (whose role in LA
pathogenesis had remained unclear until now) display
the potential to guide the adaptive immune response
during arthritis onset.
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